Nirvana Life Sciences Inc. report the development of a more efficient method for producing MDMA. Nirvana Life Sciences Inc. announced the development of a novel method of producing MDMA (3,4-methylenedioxy methamphetamine) that greatly reduces manufacturing time. This 3-step synthesis, starting from the precursor safrole, takes as little as 24 hours to complete, depending upon which method of reduction of the ketone to the secondary amine is being used.

This is approximately one third of the time that's required to complete current production methods using iso-safrole as an intermediate. Nirvana has filed an Application with the US Patent Office for this invention. MDMA was first synthesized in 1912, but it was not researched for its therapeutic potential until just recently.

The drug is a potent central nervous system (CNS) stimulant the varies greatly in effect from other common stimulants found in the same phenethylamine family of compounds. It is currently being studied and used for the treatment of a wide range of psychiatric disorders such as Post Traumatic Stress Disorder (PTSD), depression and anxiety to name a few. MDMA assisted psychotherapy is currently in phase three clinical trials for the treatment of PTSD in the US, Canada, and Israel.

This year the FDA expanded access to MDMA, allowing for its compassionate use in clinical settings by patients who have had no success with other FDA approved treatment options. MDMA effectively shuts down the brain's fight-or-flight response and creates a sense of empathy in patients, allowing them to process trauma more effectively. The drug increases the amount of serotonin in the synaptic clefts of serotonergic neurons.

It also binds to various serotonin receptors and activates them in excess, while simultaneously reducing the reuptake of other neurotransmitters, which is the drugs primary mechanism of action Lead chemist and Head of Innovation for Nirvana Life Sciences Inc., Robert August, was one of the first researchers to successfully crystallize MDMA HCl Monohydrate, a novel form of MDMA with increased bioavailability and efficacy. The method of synthesis that he developed can also be seamlessly integrated into the production of MDMA HCl Monohydrate, of which Nirvana Life Sciences Inc. recently announced a patent pending for. With the growing surge in interest in the research of MDMA in the past few years, and the increasing potentials of its use in therapeutic settings, Nirvana believes that this breakthrough is a significant advance in the emerging psychedelic medicines space.